ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRespiratory syncytial virus-associated acute respiratory illness (RSV-ARI) is an underrecognized cause of illness in older adults aged ≥ 75 years (OAs) and individuals at increased risk (AIR), contributing to a substantial disease burden. AS01E-adjuvanted RSV PreFusion protein 3 vaccine (aRSVPreF3) is approved for the prevention of RSV-associated lower respiratory tract disease (LRTD) in OAs. This study assesses the cost-effectiveness of a single dose of aRSVPreF3 vaccine among OAs and AIR individuals aged 60-74 years over 5 years in Italy.
methodsA static multi-cohort Markov model with 5-year horizon and 1-month cycle length was developed to model the effect of aRSVPreF3 vaccination. Inputs were obtained from national databases and scientific literature. Sensitivity analyses were performed to assess the robustness of the results to variations in input parameters.
resultsAt 75% coverage, aRSVPreF3 vaccination was predicted to prevent 1,253,641 and 1,083,247 RSV-ARI cases, and 552,517 and 579,008 RSV-LRTD cases, with direct healthcare costs reduced by €240,849,821 and €331,050,265 over a 5-year period in OAs and AIR individuals, respectively. Vaccination of OAs and AIR individuals was estimated to prevent 58,129 and 102,786 quality-adjusted life-year losses, yielding incremental cost-effectiveness ratios of €13,832 and €4,529, respectively.
conclusionsVaccination of OAs and AIR individuals with one dose of aRSVPreF3 has the potential to reduce RSV disease-associated burden and direct costs for the Italian National Healthcare System over a 5-year period. These results could support policymakers and clinicians in decision-making processes around the recommendation and implementation of RSV vaccination in Italy.
Indexed as
Identifiers
42565962What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.